Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Mesoblast participates in a conference call hosted by SunTrust » 04:55
07/27/20
07/27
04:55
07/27/20
04:55
MESO

Mesoblast

$12.43 /

+0.18 (+1.47%)

Conference call with…

Conference call with management to be held on July 27 hosted by SunTrust.

ShowHide Related Items >><<
MESO Mesoblast
$12.43 /

+0.18 (+1.47%)

MESO Mesoblast
$12.43 /

+0.18 (+1.47%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
MESO Mesoblast
$12.43 /

+0.18 (+1.47%)

MESO Mesoblast
$12.43 /

+0.18 (+1.47%)

Hot Stocks
Mesoblast names Dagmar Rosa-Bjorkeson as COO » 06:02
07/24/20
07/24
06:02
07/24/20
06:02
MESO

Mesoblast

$12.25 /

-0.24 (-1.92%)

, TAK

Takeda Pharmaceutical

$17.35 /

-0.105 (-0.60%)

Mesoblast (MESO)…

Mesoblast (MESO) announced the appointment of Dagmar Rosa-Bjorkeson to the role of COO, based in New York. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development and operational execution. Recently, Rosa-Bjorkeson served as Executive Vice President and President, Biosimilars, at Baxalta, now a wholly owned subsidiary of Takeda Pharmaceutical (TAK).

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.35 /

-0.105 (-0.60%)

MESO Mesoblast
$12.25 /

-0.24 (-1.92%)

MESO Mesoblast
$12.25 /

-0.24 (-1.92%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
TAK Takeda Pharmaceutical
$17.35 /

-0.105 (-0.60%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.35 /

-0.105 (-0.60%)

TAK Takeda Pharmaceutical
$17.35 /

-0.105 (-0.60%)

MESO Mesoblast
$12.25 /

-0.24 (-1.92%)

TAK Takeda Pharmaceutical
$17.35 /

-0.105 (-0.60%)

MESO Mesoblast
$12.25 /

-0.24 (-1.92%)

Conference/Events
Mesoblast participates in a conference call hosted by SunTrust » 10:31
07/21/20
07/21
10:31
07/21/20
10:31
MESO

Mesoblast

$12.73 /

+0.77 (+6.44%)

Conference call with…

Conference call with management to be held on July 27 hosted by SunTrust.

ShowHide Related Items >><<
MESO Mesoblast
$12.73 /

+0.77 (+6.44%)

MESO Mesoblast
$12.73 /

+0.77 (+6.44%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
MESO Mesoblast
$12.73 /

+0.77 (+6.44%)

MESO Mesoblast
$12.73 /

+0.77 (+6.44%)

Conference/Events
Mesoblast participates in a conference call with Cantor Fitzgerald » 07:25
07/13/20
07/13
07:25
07/13/20
07:25
MESO

Mesoblast

$13.08 /

+0.025 (+0.19%)

Conference call with…

Conference call with management will be held on July 13 at 8 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

Conference/Events
Mesoblast participates in a conference call with Cantor Fitzgerald » 04:55
07/13/20
07/13
04:55
07/13/20
04:55
MESO

Mesoblast

$13.08 /

+0.025 (+0.19%)

Conference call with…

Conference call with management will be held on July 13 at 8 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

MESO Mesoblast
$13.08 /

+0.025 (+0.19%)

Over a month ago
Conference/Events
Mesoblast participates in a conference call with Cantor Fitzgerald » 16:56
07/09/20
07/09
16:56
07/09/20
16:56
MESO

Mesoblast

$13.06 /

+0.165 (+1.28%)

Conference call with…

Conference call with management will be held on July 13 at 8 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MESO Mesoblast
$13.06 /

+0.165 (+1.28%)

MESO Mesoblast
$13.06 /

+0.165 (+1.28%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
MESO Mesoblast
$13.06 /

+0.165 (+1.28%)

MESO Mesoblast
$13.06 /

+0.165 (+1.28%)

Hot Stocks
Mesoblast says EAP initiated in U.S. for remestemcel-L for treatment of MIS-C » 06:11
07/06/20
07/06
06:11
07/06/20
06:11
MESO

Mesoblast

$12.04 /

+0.55 (+4.79%)

Mesoblast announced that…

Mesoblast announced that an expanded access protocol, or EAP, has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell, or MSC, product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome, or MIS-C. Mesoblast said in a release, "Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within five days of referral under the EAP. The protocol was filed with the FDA and provides physicians with access to remestemcel-L for an intermediate-size patient population1 under Mesoblast's existing Investigational New Drug, or IND, application. According to the FDA, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. MIS-C is a life-threatening complication of COVID-19 in otherwise healthy children and adolescents that includes massive simultaneous inflammation of multiple critical organs and their vasculature. In approximately 50% of cases this inflammation is associated with significant cardiovascular complications that directly involve heart muscle and may result in decreased cardiac function. In addition, the virus can result in dilation of coronary arteries with unknown future consequences. Recent articles from Europe and the United States have described this disease in detail."

ShowHide Related Items >><<
MESO Mesoblast
$12.04 /

+0.55 (+4.79%)

MESO Mesoblast
$12.04 /

+0.55 (+4.79%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
MESO Mesoblast
$12.04 /

+0.55 (+4.79%)

MESO Mesoblast
$12.04 /

+0.55 (+4.79%)

On The Fly
Trump Effect: Analyst questions NYT 'agenda' after COVID funding article » 11:03
06/22/20
06/22
11:03
06/22/20
11:03
CTSO

CytoSorbents

$8.84 /

-0.13 (-1.45%)

, ATHX

Athersys

$2.39 /

+0.465 (+24.16%)

, MESO

Mesoblast

$12.84 /

-0.86 (-6.28%)

, PSTI

Pluristem

$7.35 /

-0.3 (-3.92%)

Dawson James analyst…

Open Full Text

ShowHide Related Items >><<
PSTI Pluristem
$7.35 /

-0.3 (-3.92%)

MESO Mesoblast
$12.84 /

-0.86 (-6.28%)

CTSO CytoSorbents
$8.84 /

-0.13 (-1.45%)

ATHX Athersys
$2.39 /

+0.465 (+24.16%)

CTSO CytoSorbents
$8.84 /

-0.13 (-1.45%)

06/02/20 B. Riley FBR
CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR
05/14/20 B. Riley FBR
CytoSorbents label expansion could significantly expand use, says B. Riley FBR
05/06/20 B. Riley FBR
B. Riley boosts CytoSorbents target, says Portola deal highlights value
03/25/20 Dawson James
CytoSorbents being used for COVID-19 in Italy, China, says Dawson James
ATHX Athersys
$2.39 /

+0.465 (+24.16%)

06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
04/23/20 SMBC Nikko
Athersys initiated with an Outperform at SMBC Nikko
08/26/19 Dawson James
Athersys initiated with a Buy at Dawson James
MESO Mesoblast
$12.84 /

-0.86 (-6.28%)

05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
PSTI Pluristem
$7.35 /

-0.3 (-3.92%)

06/19/20 Jefferies
Pluristem initiated with a Buy at Jefferies
04/24/20 H.C. Wainwright
Pluristem removed overhang with loan agreement, says H.C. Wainwright
04/13/20 Maxim
Pluristem price target raised to $12 from $8 at Maxim
CTSO CytoSorbents
$8.84 /

-0.13 (-1.45%)

CTSO CytoSorbents
$8.84 /

-0.13 (-1.45%)

ATHX Athersys
$2.39 /

+0.465 (+24.16%)

MESO Mesoblast
$12.84 /

-0.86 (-6.28%)

CTSO CytoSorbents
$8.84 /

-0.13 (-1.45%)

ATHX Athersys
$2.39 /

+0.465 (+24.16%)

PSTI Pluristem
$7.35 /

-0.3 (-3.92%)

MESO Mesoblast
$12.84 /

-0.86 (-6.28%)

Recommendations
Channel checks dispute NY Times' COVID contention, says Dawson James » 09:20
06/22/20
06/22
09:20
06/22/20
09:20
ATHX

Athersys

$1.93 /

-0.945 (-32.93%)

, PSTI

Pluristem

$7.65 /

+0.3 (+4.08%)

, MESO

Mesoblast

$13.70 /

-0.02 (-0.15%)

, NYT

New York Times

$41.92 /

-0.66 (-1.55%)

Dawson James analyst…

Dawson James analyst Jason Kolbert said a New York Times article suggesting that BARDA is now focusing only on vaccines and abandoning late-stage therapies that can help acute COVID-19 patients recover from Acute Respiratory Distress Syndrome, or ARDS, "gets it wrong again" as his channel checks with Athersys (ATHX) Mesoblast (MESO) and Pluristem (PSTI) "all suggest it isn't so." Kolbert, who contends that the New York Times (NYT) "now has an 'open' agenda to defeat Trump and make all things Trump look bad," sees these therapeutics - MultiStem for Athersys and similar approaches from Mesoblast and Pluristem - as "viable and critical" to late-stage ARDS patients, he tells investors. He has Buy ratings on all three stocks mentioned.

ShowHide Related Items >><<
PSTI Pluristem
$7.65 /

+0.3 (+4.08%)

NYT New York Times
$41.92 /

-0.66 (-1.55%)

MESO Mesoblast
$13.70 /

-0.02 (-0.15%)

ATHX Athersys
$1.93 /

-0.945 (-32.93%)

ATHX Athersys
$1.93 /

-0.945 (-32.93%)

04/23/20 SMBC Nikko
Athersys initiated with an Outperform at SMBC Nikko
08/26/19 Dawson James
Athersys initiated with a Buy at Dawson James
PSTI Pluristem
$7.65 /

+0.3 (+4.08%)

06/19/20 Jefferies
Pluristem initiated with a Buy at Jefferies
04/24/20 H.C. Wainwright
Pluristem removed overhang with loan agreement, says H.C. Wainwright
04/13/20 Maxim
Pluristem price target raised to $12 from $8 at Maxim
04/07/20 H.C. Wainwright
Early COVID-19 results 'a game changer' for Pluristem, says H.C. Wainwright
MESO Mesoblast
$13.70 /

-0.02 (-0.15%)

05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
10/22/19 Cantor Fitzgerald
Mesoblast assumed with an Overweight at Cantor Fitzgerald
NYT New York Times
$41.92 /

-0.66 (-1.55%)

06/15/20 JPMorgan
New York Times price target raised to $50 from $42 at JPMorgan
06/12/20 Loop Capital
News Corp price target raised to $18 from $16 at Loop Capital
04/23/20 Evercore ISI
New York Times downgraded to In Line from Outperform at Evercore ISI
11/07/19 JPMorgan
New York Times earnings selloff a 'great buying opportunity,' says JPMorgan
NYT New York Times
$41.92 /

-0.66 (-1.55%)

NYT New York Times
$41.92 /

-0.66 (-1.55%)

ATHX Athersys
$1.93 /

-0.945 (-32.93%)

NYT New York Times
$41.92 /

-0.66 (-1.55%)

MESO Mesoblast
$13.70 /

-0.02 (-0.15%)

ATHX Athersys
$1.93 /

-0.945 (-32.93%)

PSTI Pluristem
$7.65 /

+0.3 (+4.08%)

NYT New York Times
$41.92 /

-0.66 (-1.55%)

MESO Mesoblast
$13.70 /

-0.02 (-0.15%)

Hot Stocks
Mesoblast: Remestemcel-L improves respiratory, functional outcomes in COPD » 06:02
06/01/20
06/01
06:02
06/01/20
06:02
MESO

Mesoblast

$12.81 /

+0.14 (+1.10%)

Mesoblast announced that…

Mesoblast announced that treatment with its lead mesenchymal stem cell product candidate remestemcel-L in patients with chronic obstructive pulmonary disease and an elevated state of inflammation resulted in improved respiratory and functional outcomes. The results were presented as a virtual oral presentation delivered to the 2020 International Society for Cell & Gene Therapy annual meeting held May 28-29, 2020. The post-hoc analysis from a randomized, placebo-controlled 60-patient Phase 2 trial in patients with COPD showed that remestemcel-L, given in four monthly intravenous doses of 100M cells, significantly improved respiratory and functional clinical outcomes in patients with elevated levels of the inflammatory biomarker C-reactive protein. Significantly elevated CRP levels are predictive of increased hospitalization and death in patients with COPD1, and are seen in various acute lung diseases, including acute respiratory distress syndrome, a life-threatening complication of COVID-19. These results support the potential of remestemcel-L to effectively treat inflammatory lung diseases, such as acutely decompensated COPD and ARDS.

ShowHide Related Items >><<
MESO Mesoblast
$12.81 /

+0.14 (+1.10%)

MESO Mesoblast
$12.81 /

+0.14 (+1.10%)

05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
05/28/20 H.C. Wainwright
Mesoblast price target raised to $21 from $14 at H.C. Wainwright
04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
10/22/19 Cantor Fitzgerald
Mesoblast assumed with an Overweight at Cantor Fitzgerald
MESO Mesoblast
$12.81 /

+0.14 (+1.10%)

MESO Mesoblast
$12.81 /

+0.14 (+1.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.